SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund (VCX) has experienced explosive volatility and intense retail interest following its recent NYSE debut, with the community actively debating whether the significant premium over its net asset value represents a massive opportunity or a classic pump-and-dump scheme. Investors are closely monitoring the impact of a 180-day lock-up period on the float, as bulls speculate on potential AI-driven gains from core holdings like Anthropic and SpaceX while skeptics warn of an imminent correction.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased volatility as investors weigh the stock's role as a defensive holding against regulatory risks and uncertainties surrounding upcoming Medicare Advantage rate announcements. While the community remains divided between those capitalizing on short-term technical swings and those banking on a long-term recovery driven by the stock's fundamental scale and dividend stability, recent sentiment is being heavily influenced by broader institutional rebalancing and sector-wide regulatory scrutiny.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

The SPERMWHALE meme coin is driving intense community debate over whether it represents a high-potential speculative play or a classic pump-and-dump scheme. Traders are actively comparing its viral potential to other successful meme tokens while others remain highly skeptical of its lack of intrinsic utility.

Merlin, Inc. is an aerospace and defense technology company focused on developing autonomous flight solutions. The company is building an operating system of record for autonomous aviation, with its Merlin Pilot system enabling a wide range of aircraft and mission profiles. Its technology has been validated through hundreds of autonomous flights conducted at test facilities worldwide. The company is headquartered in Boston, MA.

Merlin Inc.

Marlin Business Services Corp.

Marlin Business Services is currently facing significant community debate and uncertainty as investors weigh reports of potential acquisitions against ongoing legal investigations and insider trading activity. The conversation remains highly fragmented, with participants questioning the stock's future direction while closely monitoring SEC filings for signs of corporate restructuring or leadership changes.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly Inc. is capturing significant investor attention as it continues an aggressive, volatility-driven rally that has traders debating whether the stock is a breakout AI-focused momentum play or an overextended bubble nearing a potential correction. The community remains deeply divided, with bulls pointing to strong institutional accumulation and cloud sector tailwinds, while vocal bears highlight heavy insider selling and the absence of fundamental profitability as catalysts for a looming reversal.

The Graph is an indexing protocol and global API for organizing blockchain data and making it easily accessible with GraphQL. Developers can use Graph Explorer to search, find, and publish all the public data they need to build decentralized applications. The Graph Network makes it possible to build serverless dApps that run entirely on public infrastructure.  GRT is the native token of the network that’s used to coordinate work. GRT is an ERC20 token. Node operators, called Indexers, stake and earn GRT for processing queries. Anyone can delegate GRT to Indexers to secure the network and earn rewards. Curators organize data on The Graph by signaling GRT on useful APIs, called subgraphs. Indexers, Delegators, and Curators work together to organize the data for the crypto economy and maintain a useful global API for DeFi and Web3.

The Graph

The Graph is capturing significant community attention as investors debate its role as critical AI and Web3 infrastructure amidst ongoing accumulation and volatility. While some sentiment is cautious due to historical price trends and supply dilution, bulls are highlighting recent technical developments, like the Horizon Mainnet upgrade and cross-chain staking, as key catalysts for a potential reversal.

FUST (Fusion token) is the companion token of FUSD - with tokenomics which mirror those of a typical cryptocurrency. FUST can be placed in the FUST Fusion Miner and used to mine free FUSD. FUST has tokenomics which mirror those of a typical cryptocurrency, and allows those Degens who buy into the FUSD philosophy - but who also enjoy the thrill of chasing fast green candles - to make their play within the structure of the FUSD ecosystem and benefit from the best of both worlds; the possibility of a fast ride upwards whilst earning a passive income paid in our appreciating stable token courtesy of their FUST bag.

FUST Token

The FUST community is buzzing over its unique ecosystem, which focuses on generating passive income through an appreciating stablecoin, FUSD, rather than relying solely on speculative price action. Investors are actively discussing the platform's yield-generating model and rumored upcoming distribution events as key drivers for potential long-term momentum.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

The 4CHAN community is currently rallying behind the token as the definitive "source code" and index for meme culture, emphasizing its massive supply of zeros and potential for high-risk, high-reward gains. Discussions center on the asset's resilience against market volatility, with holders actively promoting it as an uncensorable, organic alternative to more centralized memecoins.

The Estée Lauder Companies, Inc. engages in the manufacture of skin care, makeup, fragrance and hair care products. It sells products under Estée Lauder, Clinique, Origins, MAC, Bobbi Brown, La Mer, Jo Malone London, Aveda and Too Faced. The company was founded by Estee Lauder and Joseph Lauder in 1946 and is headquartered in New York, NY.

Estee Lauder Cos., Inc. - Ordinary Shares - Class A

Estee Lauder Cos. Inc

Estee Lauder is in the spotlight as investors debate the impact of potential merger talks with Spanish beauty group Puig, a move that community members view as a strategic play to achieve global scale amid the company's broader turnaround efforts. While some discuss the long-term potential of this consolidation, others are closely tracking how tariff-related headwinds and integration risks could influence share price volatility.

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Sutro Biopharma Inc

Sutro Biopharma is trending as investors weigh potential partnership developments for its Luvelta program alongside the company's strategic pivot toward its next-generation exatecan and dual-payload ADC pipeline. Community sentiment is deeply divided, with many long-term shareholders expressing frustration over recent stock volatility and organizational restructuring, while others remain optimistic that the company's substantial cash position and preclinical collaborations could eventually drive value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Atomera’s stock offering is at a discount of 40% when compared to the closing price on Friday.</li><li>The company stated that it intends to use the funds raised through the stock offering to meet its working capital requirements and other general corporate needs.</li><li>Atomera added that the stock offering is expected to close on or about Feb. 24, 2026.</li></ul>Atomera Inc. (ATOM) stock declined nearly 13% in Monday’s opening trade after the company announced the pricing of a new stock offering.Atomera announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share. This is at a discount of 40% from the stock’s closing price on Friday.<h2 class="st-heading-2">What Will Atomera Use The Funds For?</h2>Atomera stated in its announcement that it intends to use the funds raised through the stock offering to meet its working capital requirements and other general corporate needs.The company added that the stock offering is expected to close on or about Feb. 24, 2026.Atomera reported its fourth-quarter (Q4) results earlier this month, posting a loss of $0.14 per share, in line with Wall Street expectations. The company reported revenue of $0.05 million, while the consensus estimate was $0.1 million, according to Stocktwits data.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ATOM">Atomera</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.Despite Atomera’s share price decline, one bullish user said it's a buying opportunity.<stembedurl>https://stocktwits.com/BioRocket/message/645608846</stembedurl>Another user stated they’re surprised by Atomera’s stock offering, noting that the company didn't need cash.<stembedurl>https://stocktwits.com/DinoMcnuggets/message/645607759</stembedurl><a href="https://stocktwits.com/symbol/ATOM">ATOM stock</a> is up 217% year-to-date and 9% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palo-alto-networks-removed-from-wedbush-best-ideas-list/cZRtp2lR4ya">Palo Alto Networks Removed From Wedbush’s ‘Best Ideas List’ — Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Atomera Incorporated logo is seen displayed on a smartphone and pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

ATOM Stock Is Falling Today After Atomera Announces Stock Offering At A Deep Discount

The company announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share.

Equity

Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Evommune stated that it designed the Phase 2a trial to evaluate the safety and efficacy of an intravenous 5 milligram per kilogram dose of EVO301 over 12 weeks.</li><li>The company said it had 70 patients in the trial, and EVO301 achieved a 33% placebo-adjusted improvement in the Eczema Area and Severity Index at week 12.</li><li>Evommune said EVO301 showed a favorable safety profile with no serious adverse events reported.</li></ul>Evommune Inc. (EVMN) shares nearly doubled in value in Tuesday’s pre-market trade before paring some of the gains to hover 50% higher in the opening trade after the company reported positive results from its atopic dermatitis trial.Evommune stated that its atopic dermatitis treatment, EVO301, met its primary endpoint at week 12 during the&nbsp;mid-stage trial. The company said that EVO301 achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis.Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/EVMN">Evommune</a> trended in the ‘neutral’ territory at the time of writing. The EVMN stock was among the top five trending tickers on the platform.<h2 class="st-heading-2">Evommune Details Results Of The Trial</h2>Evommune stated that it designed the Phase 2a trial to evaluate the safety and efficacy of an intravenous 5 milligram per kilogram dose of EVO301 over 12 weeks.“These data support our plans to move EVO301 into a Phase 2b dose-ranging trial where we can optimize the dose and seek to further improve patient outcomes,” said Evommune President and CEO, Luis Peña.The company said it had 70 patients in the trial, and EVO301 achieved a 33% placebo-adjusted improvement in the Eczema Area and Severity Index (EASI) at week 12.Evommune said EVO301 showed a favorable safety profile, with no serious adverse events reported and no treatment-related discontinuations due to adverse events.Dr. Mark G. Lebwohl, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, stated that EVO301’s ability to target the interleukin-18 (IL-18) mechanism and demonstrate clinically relevant activity could present patients with “real benefits.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One bullish user stated that there has been “only good news” with the Evommune stock so far.<stembedurl>https://stocktwits.com/swingingg/message/644564885</stembedurl>Another user stated that the IL-18, a known inflammatory pathway which plays a key role in various immune processes, is “working great” for dermatitis.<stembedurl>https://stocktwits.com/JanetBSmellin/message/644548490</stembedurl><a href="https://stocktwits.com/symbol/EVMN">EVMN stock</a> is up 45% year-to-date and 44% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/michael-saylor-bitcoin-volatility-bug-as-well-as-feature/cZbUI8AR4Yx">Michael Saylor Calls Bitcoin Volatility Both A Bug And A Feature, Touts It As ‘Digital Capital’: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?

The company said that EVO301 achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis.

<ul class="summary-bullets"><li>In Kentucky, TeraWulf has acquired a former industrial site in Hawesville, which has approximately 480 MW of existing power availability.</li><li>In Maryland, where TeraWulf is headquartered, the company has acquired the Morgantown Generating Station.</li><li>This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually.</li></ul>Shares of TeraWulf (<a href="https://stocktwits.com/symbol/WULF">WULF</a>) surged more than 10% during extended hours of trading on Monday after the company announced that it is expanding its digital and power infrastructure portfolio.&nbsp;The company said it is expanding its portfolio through the acquisition of two strategically located brownfield infrastructure sites in Hawesville, Kentucky and Charles County, Maryland.<h2 class="st-heading-2">Details</h2>TeraWulf said these acquisitions added about 1.5 gigawatts (GW) of capacity to its portfolio and advanced the company’s strategy of developing energy-advantaged locations with near-term power availability, long-term scalability, and the ability to support customer demand and broader grid needs.In Kentucky, TeraWulf has acquired a former industrial site in Hawesville. The site includes more than 250 buildable acres for compute capacity and offers immediate access to robust power infrastructure, the statement said.&nbsp;The Hawesville site has approximately 480 megawatts (MW) of existing power availability, with the potential to further expand over time. Development is expected to occur in phases, allowing TeraWulf to scale efficiently alongside customer demand.In Maryland, where TeraWulf is headquartered, it has acquired the Morgantown Generating Station. The acquisition establishes TeraWulf’s presence in the Pennsylvania-New Jersey-Maryland (PJM) market and reinforces the company’s strategy of reinvesting in existing energy assets to support grid reliability and long-term economic activity.<h2 class="st-heading-2">Portfolio Expansion</h2>With the addition of these sites, TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites, including 642.5 MW of contracted capacity and 2.2 GW of owned pipeline capacity.This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually, aligned with customer demand, power availability, and regional grid conditions.“These acquisitions reflect our strategy of reinvesting in existing energy infrastructure to support grid reliability, long-term economic activity, and responsible growth,” said Paul Prager, Chairman and Chief Executive Officer of TeraWulf.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around WULF trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;One bullish user said that “2 additional site announcement today DOUBLES the AI/HPC capacity”.&nbsp;<stembedurl>https://stocktwits.com/AllMarkets/message/643740254</stembedurl>Shares in the company have jumped more than 200% over the past 12 months.&nbsp;&nbsp;

 In this photo illustration, the TeraWulf (Tera Wulf) logo is seen displayed on a smartphone screen.

Why Is TeraWulf Stock Rallying More Than 10% After Hours?

With the addition of these sites, TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites.

<ul class="summary-bullets"><li>The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab without Anktiva.</li><li>Durable complete responses were observed in heavily pretreated patients with iNHL in the study, including Waldenström’s Macroglobulinemia, the company said.</li><li>Last month, Immunitybio said that it recently met with the U.S. FDA to discuss its application for Anktiva plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.</li></ul>Immunitybio Inc. (IBRX) said on Monday that it has launched a mid-stage clinical study in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) with no need for chemotherapy.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell">said</a> that outpatient study will evaluate ImmunityBio’s novel, off-the-shelf cell therapy CD19 CAR-NK in combination with its other drug Anktiva and Rituximab, and will not require any lymphodepleting chemotherapy unlike conventional CAR-T cell therapies.<h2 class="st-heading-2">Why The Trial?</h2>The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab without Anktiva. Durable complete responses were observed in heavily pretreated patients with iNHL in the study, including Waldenström’s Macroglobulinemia, the company said.The new mid-stage study is designed to evaluate whether further stimulation of innate and adaptive immune responses may enhance the depth and durability of anti-tumor activity, Immunitybio said, while adding that the company is hopeful for Anktiva potentially augmenting the actions of the cell therapy and Rituximab.The study will enroll patients with indolent NHL, including Waldenström’s Macroglobulinemia, who are relapsed or are refractory after at least two prior lines of therapy. Treatment will be provided without chemotherapy.<h2 class="st-heading-2">Anktiva Troubles</h2>Last month, Immunitybio said that it recently met with the U.S. Food and Drug Administration to discuss its application for Anktiva plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.The company had submitted the application in 2025 but was rejected and is now looking to resubmit it with more information. The company then said that it would submit the additional information within 30 days, and that the added information does not need a new trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IBRX shares remained within the ‘bullish’ territory, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained about 90% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-seemingly-confirms-xai-spacex-merger-talks/cZbgtmrR4kZ">Elon Musk Seemingly Confirms xAI-SpaceX Merger Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs

The company said that outpatient study will evaluate ImmunityBio’s novel, off-the-shelf cell therapy CD19 CAR-NK in combination with its other drug Anktiva and Rituximab.

<ul class="summary-bullets"><li>For the full fiscal year 2026, the company now expects total revenue in the range of $435 million to $440 million, compared to prior guidance of $425 to $435 million.</li><li>For the current quarter (Q2), the company expects to report revenue of approximately $107 million to $108 million, marking a growth of approximately 16% percent year over year.</li><li>Twist also said that it expects to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.</li></ul>Shares of Twist Bioscience Corporation (TWST) jumped 8% on Monday after the company hiked its fiscal year 2026 revenue guidance on the heels of a first-quarter (Q1) earnings report that beat Wall Street estimates.<h2 class="st-heading-2">Upbeat Outlook</h2>For the full fiscal year 2026, the company now expects total revenue in the range of $435 million to $440 million, compared to prior guidance of $425 to $435 million, and exceeding an analyst estimate of $430.84 million, according to data from Fiscal AI. &nbsp;For the current quarter (Q2), the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.twistbioscience.com/static-files/af6dbd56-d91e-429e-b337-a8e2675fc255">expects</a> to report revenue of approximately $107 million to $108 million, marking a growth of about 16% percent year over year at the midpoint, and exceeding an estimated $105.08 million.Twist also said that it expects to achieve adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) breakeven in the fourth-quarter of fiscal 2026.<h2 class="st-heading-2">Q1 Numbers</h2>For Q1, the company reported total revenue of $103.7 million, marking a growth of 17%, and above an expected $100.33 million, due to an increase in customers. The company said that it shipped products to about 2,538 customers in Q1 of fiscal 2026, versus approximately 2,376 in the same quarter of the previous fiscal year.Net loss for the quarter came in at $30.5 million, compared to $31.6 million in the corresponding quarter of fiscal 2025.The company also ended the quarter with $198 million in cash, cash equivalents, and short-term investments.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TWST stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A user applauded the earnings as “solid” progress for investors.<stembedurl>https://www.stocktwits.com/DBRGLong/message/643661292</stembedurl><a href="https://stocktwits.com/symbol/TWST">TWST stock</a> has dropped 16% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/oracle-bond-offering-funding-ai-cloud-infrastructure/cZbgYA1R4ki">ORCL Stock In Focus As Tech Giant Reportedly Launches Bond Offering To Cover Half Of 2026 Funding Needs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TWST Shares Rise 8% — What’s Driving The Rally?

Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates. 

<ul class="summary-bullets"><li>The committee had issued a negative opinion on approving the new dosing regimen in October after it deemed the submitted data as insufficient to conclude on efficacy.</li><li>Protalix said that it will be eligible to receive a regulatory milestone payment of $25 million from Chiesi Global Rare Diseases if the new dosing regimen is approved by the EMA.</li></ul>Shares of Protalix BioTherapeutics, Inc. (PLX) closed 13% higher on Friday after it announced that a European Medicines Agency committee has recommended approval of a new dosing regimen for pegunigalsidase alfa, marketed as Elfabrio, in Fabry disease.The Committee for Medicinal Products for Human Use <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.protalix.com/news-releases/news-release-details/chiesi-global-rare-diseases-and-protalix-biotherapeutics-4">recommended</a> approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients. Currently approved dosing regimen requires patients to visit infusion centers every two weeks for treatment while the proposed new regimen would allow it to be stretched to every four weeks.<h2 class="st-heading-2">Turnaround</h2>The positive opinion follows CHMP’s re-examination of the company’s application for the additional dosing regimen. The committee had issued a negative opinion on approving the new dosing regimen in October after it deemed the submitted data as insufficient to conclude on efficacy.Protalix said that it will be eligible to receive a regulatory milestone payment of $25 million from Chiesi Global Rare Diseases if the new dosing regimen is approved by the EMA. The agency is expected to announce a decision by March 2026.Fabry disease is a rare, inherited X-linked lysosomal storage disorder caused by a deficiency in the alpha-galactosidase A enzyme, leading to harmful accumulation of fats in cells. Symptoms include severe neuropathic pain in hands/feet, skin lesions, decreased sweating, and organ damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PLX stock improved from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user appreciated that the company was persistent in getting a positive opinion. However, the stock should have rallied more on the news, they said.“But the $25 million is great news and hopefully should lessen the risk of capital raise for their gout trials. Finally, one decent obstacle out of the way,” they wrote.<stembedurl>https://www.stocktwits.com/BryGuy29/message/643515194</stembedurl><a href="https://stocktwits.com/symbol/PLX">PLX stock</a> has dropped about 2% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/peloton-reportedly-lays-off-11-percent-workforce/cmySvT7R4Sv">Peloton Reportedly Lays Off 11% Workforce Including Engineers In Cost-Cutting Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy

The Committee for Medicinal Products for Human Use recommended approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients.

<ul class="summary-bullets"><li>Attorney General's petition for review challenges PHMSA’s attempt to evade state regulation through its orders to federalize the Las Flores Pipelines.</li><li>Sable in December had said that it received a receipt of an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.&nbsp;</li><li>The onshore pipelines have been shut down for a decade since the 2015 Refugio Beach oil spill.&nbsp;</li></ul>Sable Offshore shares plunged more than 14% on Friday after its two California pipeline restart came under scrutiny from a California Attorney General.&nbsp;California Attorney General Rob Bonta on Friday filed a lawsuit against the Trump Administration, challenging the Pipeline and Hazardous Materials Safety Administration’s (PHMSA) orders that “illegally assert” exclusive jurisdiction over two California onshore oil pipelines of Sable offshore which are known as the Las Flores Pipelines or lines CA-324 and CA-325, and allow them to restart operations.<h2 class="st-heading-2">Lawsuit Details</h2>Filed in the United States Court of Appeals for the Ninth Circuit, the Attorney General's petition for review challenges PHMSA’s alleged attempt to evade state regulation through its orders to federalize the Las Flores Pipelines, approve Sable Offshore’s restart plan, and issue Sable an emergency permit to restart oil transport through the pipelines.California Attorney General Rob Bonta, in a statement, said the administration broke the law by reclassifying the Las Flores pipelines last month as "interstate" even though they run between two California counties and are subject to state regulation.&nbsp;“In its latest unlawful power grab, the Trump Administration is illegally claiming exclusive federal authority over two of California's onshore pipelines. California has seen first-hand the devastating environmental and public health impacts of coastal oil spills — yet the Trump Administration will stop at nothing to evade state regulation which protects against these very disasters,” Bonta in a statement.&nbsp;<h2 class="st-heading-2">Sable’s Pipelines</h2>Sable in December had said that it received a receipt of an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.&nbsp;“PHMSA has issued an emergency special permit for segments of the interstate Santa Ynez Pipeline System (specifically segments 324 and 325), approving the Company’s implementation of enhanced integrity management practices and specifying operational conditions,” it said in a statement.&nbsp;The onshore pipelines have been shut down for a decade since the 2015 Refugio Beach oil spill, when a corroded segment of one pipeline ruptured and released hundreds of thousands of gallons of oil near Santa Barbara.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around SOC trended in ‘bearish’ territory amid ‘extremely low’ message volume.&nbsp;Shares in the company have fallen 62% over the past 12 months.&nbsp; &nbsp;

A deserted oil factory in Maracaibo, Venezuela, pictured on December 27, 2019. (Photo by Humberto Matheus/NurPhoto via Getty Images)

Sable Offshore Plunged 14% Today – What Is The Feud With California State?

California Attorney General Rob Bonta on Friday filed a lawsuit against the Trump Administration, challenging the Pipeline and Hazardous Materials Safety Administration’s (PHMSA) orders of allowing Sable Offshore’s two pipelines to restart operations.

<ul class="summary-bullets"><li>The company said the property and equipment is located in Radersburg, Montana and was acquired for $4.75 million in cash.</li><li>The company said it has budgeted approximately $2 million in future capital expenditures to make specific equipment improvements to this facility.&nbsp;</li></ul>Shares of United States Antimony Corporation (UAMY) rallied on Friday led by optimism among retail traders who expect the stock price to double this year.&nbsp;The stock was up more than 7% at the time of writing and was among the top trending stocks on Stocktwits.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around UAMY trended in ‘extremely bullish’ territory amid ‘high’ message volume.One bullish user said that ‘sky’s the limit for the stock’.<stembedurl>https://stocktwits.com/jayrebs71/message/642708197</stembedurl>Another user predicted the stock to hit $20.<stembedurl>https://stocktwits.com/Milodino12/message/642705651</stembedurl>Shares in the company have rallied 514% over the past 12 months.&nbsp;<h2 class="st-heading-2">Recent News</h2>United States Antimony earlier in the week announced the closing of a property acquisition of a critical minerals flotation facility. The property and equipment which is located in Radersburg, Montana, between Helena and Bozeman, Montana, is fully operational, and was acquired for $4.75 million in cash, it said in a statement.The company also said that it has budgeted approximately $2 million in future capital expenditures to make specific equipment improvements to this facility.&nbsp;The Radersburg Mill is a mineral processing facility equipped with both gravity and flotation circuits enabling the concentration of many minerals including stibnite, the primary antimony mineral. The facility has crushing and grinding circuits that reduce the ore to small particles in order to "liberate" target minerals such as gold, silver, copper, tungsten or stibnite amongst many others, the company said.&nbsp; &nbsp;

In this photo illustration, the United States Antimony (US Antimony) logo is seen displayed on a smartphone screen.

Why This Small-Cap Penny Stock Is Rallying Today – Traders Expect Stock Price To Double

United States Antimony earlier in the week announced the closing of a property acquisition of a critical minerals flotation facility.

<ul class="summary-bullets"><li>BigBear.ai’s CEO Kevin McAleenan has told company shareholders that the firm is running low on available shares.</li><li>Proxy shareholder firms ISS and Glass Lewis have both recommended voting in favour of the proposal.</li><li>Company’s CFO Sean Ricker said earlier this month that the company was “97% of the way” to reaching the required votes.</li></ul>Shares of Bigbear.ai were under investors’ radar and the top trending stock on Stocktwits ahead of its shareholder vote deadline on the company's proposal to increase its authorized common stock.&nbsp;The company wants its investors to approve an amendment for increasing its authorized common shares from 500 million to 1 billion shares. The shareholder vote deadline is till 11:59 PM ET on Wednesday. The approval will be decided at a reconvened special meeting on Thursday.&nbsp;BigBear.ai’s proposal to increase the authorized shares had failed to secure enough votes last month.&nbsp;<h2 class="st-heading-2">Why It Matters</h2>Authorized shares put a legal maximum limit of shares a company can issue. Increasing the limit of authorized shares helps a company make finance acquisitions and compensate its employees with stock.&nbsp;BigBear.ai’s CEO Kevin McAleenan has told company shareholders that the firm is running low on available shares and has urged shareholders to vote in favour of the amendment. He said that approval “would not result in the immediate issuance of new shares.”Proxy shareholder firms ISS and Glass Lewis have both recommended voting in favour of the proposal, he said in a letter to shareholders. “Having access to available authorized shares has allowed us over the years to make important acquisitions, fund product development and strengthen our balance sheet,” he added.&nbsp;The letter also said that additional shares would be available in the future to help fuel the company's growth as it looks to expand its AI capabilities, invest in its technology and Research and Development, invest in attracting and retaining top talent, and evaluating and acting on opportunistic financing and strategic initiatives.&nbsp;Company’s CFO Sean Ricker <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://bigbear.ai/blog/attention-shareholders-your-proxy-vote-questions-answered/?utm_source=ts2.tech">said</a> earlier this month that the company was “97% of the way” to reaching the required votes and added that “very few shares remain” under the current authorization.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BBAI trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares of the company have fallen 2.4% year-to-date.&nbsp; &nbsp;

The BigBear.ai Holdings Inc logo appears on a smartphone screen and as a background on a laptop screen in this photo illustration in Athens, Greece.

BigBear.ai Shares Tumble 8% Ahead Of Crucial Shareholder Vote Deadline On Increasing Authorized Shares

The company wants its investors to approve an amendment for increasing its authorized common shares from 500 million to 1 billion shares.

Current Price	$231.41
Prev Close	$225.91
Open	$230.51
Dividend Yield	N/A
50-Day Moving Average	$244.89
Beta	N/A
Avg. Volume	25,861.97
PE Ratio	N/A

52-Week High	$259.59
52-Week Low	$160.03
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

VTWG
Vanguard Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VTWG News

VTWGVanguard Russell 2000 Growth ETF